Aladotes® resultat är utvald för presentation på The International Liver Congress
January 31, 2019 02:00 ET
|
PledPharma AB
Stockholm, 31 januari 2019. PledPharma AB (publ) meddelar att abstraktet med de positiva resultaten från Aladotes® Fas Ib/IIa proof of principle-studie har utvalts för muntlig presentation på den...
Aladote®’s data has been selected for presentation at The International Liver Congress
January 31, 2019 02:00 ET
|
PledPharma AB
Stockholm, January 31, 2019. PledPharma AB (publ) announces that the abstract on the positive results from the Aladote®’s Phase Ib/IIa proof of principle-study has been selected for an oral...
PledPharma presenterar resultat från studie på läkemedelskandidaten Aladote® för paracetamolförgiftning på global toxikologikonferens
December 13, 2018 02:00 ET
|
PledPharma AB
Stockholm, 13 december 2018. PledPharma AB (publ) meddelar att bolagets Aladote® fas Ib/IIa studieresultat har accepterats för presentation på den globala toxikologikonferensen ”58th Annual Meeting of...
PledPharma presents results from study on drug candidate Aladote® for paracetamol poisoning at a global toxicology conference
December 13, 2018 02:00 ET
|
PledPharma AB
Stockholm, December 13, 2018. PledPharma AB (publ) announces that the company's Aladote® Phase Ib/IIa study results has been accepted for a poster presentation during the “58th Annual Meeting of the...
PledPharma redovisar positiva slutresultat från klinisk proof of principle-studie av Aladote®
September 24, 2018 02:30 ET
|
PledPharma AB
Stockholm, 24 september 2018. PledPharma AB (publ) meddelar idag att proof of principle-studien av Aladote® framgångsrikt har slutförts, och att studiens primära syfte – att dokumentera...
Pledpharma announces positive results from the Aladote® proof of principle study
September 24, 2018 02:30 ET
|
PledPharma AB
Stockholm, September 24, 2018. Today PledPharma (publ) announces that the Aladote® proof of principle study in patients with paracetamol overdose at risk of liver damage has successfully met the...
Aladote® uppvisar god säkerhetsprofil i den första kliniska studien – PledPharma planerar ansöka om särläkemedelsstatus i USA
June 25, 2018 02:30 ET
|
PledPharma AB
PledPharma AB (publ) meddelar idag resultaten från en oberoende utvärdering av data från den kliniska proof-of-principle-studien (fas 1b/2a) av Aladote®. Utvärderingen, som utförts av studiens Data...
Aladote® is concluded as safe in first clinical study – PledPharma aims to apply for Orphan Drug Status in the US
June 25, 2018 02:30 ET
|
PledPharma AB
Today PledPharma (publ) announces that the company has received a positive conclusion of the safety evaluation from the Data Safety Monitoring Board for the Aladote proof of principle study in...
Ocera Therapeutics Announces Late-Breaker Abstract Accepted for Presentation at the AASLD Liver Meeting 2016
October 24, 2016 09:05 ET
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Oct. 24, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), today announced that clinical data from STOP-ALF, a Phase 2a clinical...
Ocera Announces Enrollment Completion From Phase 2a NIH-Sponsored Study of OCR-002 in the Treatment of Patients with Acute Liver Failure
September 21, 2016 16:05 ET
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Sept. 21, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), today announced completion of enrollment in STOP-ALF, a Phase...